Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

@article{Yu2014PracticalGF,
  title={Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.},
  author={Huixin Yu and Neeltje Steeghs and Cynthia M. Nijenhuis and Jan H. M. Schellens and Jos H. Beijnen and Alwin D. R. Huitema},
  journal={Clinical pharmacokinetics},
  year={2014},
  volume={53 4},
  pages={305-25}
}
There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM) in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between exposure and response (efficacy/toxicity) have been established for several TKIs. For example, the pharmacokinetic targets for efficacy of imatinib, sunitinib and pazopanib have been defined as trough plasma concentrations (Ctrough) of >1,000, >50 and >20,000 ng/mL for selected indications, respectively. Dose… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 15 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 143 references

Dasatinib pharmacokinetics and exposure–response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract no. 3590

X Wang, A Hochhaus, HM Kantarjian
J Clin Oncol • 2008
View 5 Excerpts
Highly Influenced

Clinical pharmacokinetics of tyrosine kinase inhibitors

NP Van Erp, H Gelderblom, H-J. Guchelaar
Cancer Treat Rev • 2009
View 5 Excerpts
Highly Influenced

( Nsclc )

Lu J-F, SM Eppler, J Wolf
2014

and Drug Administration

US Foo
http://www.fda.gov. Accessed 8 Jan • 2014
View 1 Excerpt

Activity-based kinase profiling of approved tyrosine kinase inhibitors.

Genes to cells : devoted to molecular & cellular mechanisms • 2013

Similar Papers

Loading similar papers…